Vanda $210M-$250M revenue target for 2025 amid product launches

 

• CEO Mihael Polymeropoulos highlighted Vanda’s entry into a new growth phase, driven by multiple commercialized products and an expanding pipeline. Fanapt prescriptions reached multi-year highs, surpassing 2,000 weekly prescriptions by the end of April. Total prescriptions and net product sales for Fanapt increased by 14% year-over-year, with new patient starts growing threefold.
• Vanda has expanded its psychiatry sales force to approximately 300 representatives and its PONVORY sales team to 40 representatives to support market penetration.
• The company is advancing regulatory filings, including a new drug application for Tradipitant targeting motion sickness with a PDUFA date of December 30, 2025, and a biologic license application for Imsidolimab expected later this year. Fanapt and HETLIOZ applications are also being reviewed by the European Medicines Agency.
• CFO Kevin Moran reported Q1 2025 revenues of $50 million, a 5% increase year-over-year, attributed to Fanapt’s growth. Fanapt net product sales were $23.5 million, and HETLIOZ sales were $20.9 million. PONVORY sales decreased to $5.6 million due to volume declines.

• Vanda reiterated its 2025 revenue guidance of $210 million to $250 million, reflecting growth from Fanapt, HETLIOZ, and PONVORY. End-of-year cash is projected between $280 million and $320 million.
• Management expects Fanapt’s growth trajectory to accelerate throughout the year, supported by its expanding sales force and the commercial launches of its bipolar disorder indication and PONVORY for multiple sclerosis.
• Medicare benefit redesign under the Inflation Reduction Act is anticipated to impact gross-to-net adjustments, particularly for Fanapt and HETLIOZ.

https://www.msn.com/en-us/money/savingandinvesting/vanda-pharmaceuticals-outlines-210m-250m-revenue-target-for-2025-amid-product-launches/ar-AA1EmtfH